Table 1.

Clinical endpoints for first and second phases

	Control (n=46)	Active (n=39)	p value
First phase
Number desensitised	0	24	<0·001*
Number not desensitised	46	15
Proportion desensitised	0 (0 to 0·091)	0·62 (0·45 to 0·78)	..
Proportion able to tolerate daily ingestion	0	0·84 (0·70 to 0·93)	..
Median absolute change in NOAEL, mg	0 (−95 to 45)	1345 (45 to 1400)	0·002, <0·001†
Median fold change in NOAEL, mg	0·81 (0·05 to 1·82)	25·5 (1·82 to 280)	0·003, <0·001†
Median NOAEL after first phase, mg‡	5 (5 to 400)	1400 (100 to 1400)	<0·001§
Second phase
Proportion desensitised	0·54 (0·35 to 0·72)	..	..
Proportion able to tolerate daily ingestion	0·91 (0·79 to 0·98)	..	..
Median change in FAQLQ-PF score from baseline to post-treatment	−1·41 (−4·83 to 1·38)¶	−1·61 (−4·87 to 0·24)‖	<0·001, <0·001**

Data are proportion (95% CI) or median (range). NOAEL=no observed adverse effect level. FAQLQ-PF=Food Allergy Quality of Life Questionnaire—Parent Form for 5–12 years.

^*From Fisher's exact test.

^†From Wilcoxon signed rank tests.

^‡Median difference in NOAEL between groups was 1395 mg (95% CI 395 to 1395); p<0·001 (from Mann Whitney U test).

^§From Mann Whitney U test.

^¶n=20.

^‖n=19.

^**From Wilcoxon signed rank tests.